Effect of antiprogestins and tamoxifen on growh inhibition of MCF-7 human breast cancer cells in nude mice

被引：13

作者：

El Etreby M.F. ^{[1
,2
]}

Liang Y. ^{[1
]}

机构：

[1] Department of Surgery, Medical College of Georgia, Augusta, GA

[2] Medical College of Georgia, Section of Urology, BAA-8414, Augusta

来源：

Breast Cancer Research and Treatment | 1998年 / 49卷 / 2期

关键词：

Antiestrogens (tamoxifen); Antiprogestins; (mifepristone; onapristone); Breast cancer; MCF-7; cells; Nude mice;

D O I：

10.1023/A:1006098910000

中图分类号：

学科分类号：

摘要：

This is the first report demonstrating an in vivo antitumor activity of antiprogestins (mifepristone, onapristone) alone and in combination with tamoxifen in the MCF-7 human breast cancer model. The MCF-7 cells produced progressive growing tumors in female nude mice supplemented with 17β-estradiol. Tumor regression was observed following either estrogen ablation alone or estrogen ablation in combination with tamoxifen. Monotherapy with tamoxifen or antiprogestins caused a retardation of estrogen-induced tumor progression. Complete inhibition or prevention of tumor growth occurred as a result of simultaneous administration of mifepristone and tamoxifen. The addition of mifepristone in this combination treatment was also effective in delaying or preventing tumor escape (relapse) from the antiestrogenic (antitumor) effect of tamoxifen. These results suggest a potential clinical benefit of adding an antiprogestin to antiestrogen therapy of breast cancer patients.

引用

页码：109 / 117

页数：8

共 24 条

[1]

Beier H.M., Spitz I.M., Progesterone Antagonists in Reproductive Medicine and Oncology, (1994)

[2]

Klijn J.G.M., Setyono-Han B., Sander H.J., Lamberts S.W.J., DeJong F.H., Deckers G.H., Foekens J.A., Preclinical and clinical treatment of breast cancer with antiprogestins, Progesterone Antagonists in Reproductive Medicine and Oncology, pp. 181-189, (1994)

[3]

Horwitz K.B., The molecular biology of RU 486. Is there a role for antiprogestins in the treatment of breast cancer?, Endocr Rev, 13, pp. 146-163, (1992)

[4]

Perrault D., Eisenhauer E.A., Pritchard K.I., Panasci L., Norris B., Vandenberg T., Fisher B., Phase II study of the progesterone antagonist mifepristone (RU 486) in patients with untreated metastatic breast carcinoma, J Clin Oncol, 14, pp. 2709-2712, (1996)

[5]

Robertson J.F.R., Willsher P., Blamey R.W., Onapristone, a progesterone receptor antagonist, as first line endocrine therapy in primary breast cancer, Breast Cancer Res Treat, 41, (1996)

[6]

Schneider M.R., Michna H., Nishino Y., El Etreby M.F., Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT-mammary tumor model of the mouse and the DMBA- and MNU-induced mammary tumor models of the rat, Eur J Cancer Clin Oncol, 25, 4, pp. 691-701, (1989)

[7]

Michna H., Schneider M.R., Nishino Y., El Etreby M.F., Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors

[8]

mechanistic studies, Breast Cancer Res Treat, 14, pp. 275-288, (1989)

[9]

Michna H., Schneider M.R., Nishino Y., El Etreby M.F., The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death, J Steroid Biochem Mol Biol, 34, pp. 447-453, (1989)

[10]

Schneider M.R., Michna H., Nishino Y., Neef G., El Etreby M.F., Tumor inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive experimental rodent and human mammary tumors, Anticancer Res, 10, pp. 683-688, (1990)

← 1 2 3 →